PolarityTE Inc.

PolarityTE — H.C. Wainwright Annual Global Investment Conference 2020

14 slides from PolarityTE's conference presentation, Sep 14, 2020

  1. Slide 1: H.C. Wainwright Annual Global Investment Conference

    Slide 1: H.C. Wainwright Annual Global Investment Conference

    H.C. Wainwright 224 Annual Global Investment Conference September 14, 2020—

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc, (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accurac

  3. Slide 3: Opening Remarks

    Slide 3: Opening Remarks

    @ skinte Opening Remarks David Seaburg, Chief Executive Officer

  4. Slide 4: SkinTE in the Treatment of Diabetic Foot Wounds

    Slide 4: SkinTE in the Treatment of Diabetic Foot Wounds

    SkinTE™ in the Treatment of Diabetic Foot Wounds NCT03881254 Interim Analysis Topline Results ~ Nikolai Sopko, MD, PhD, Chief Scientific Officer

  5. Slide 5: Trial Design

    Slide 5: Trial Design

    Trial Design Prospective, multi-center, randomized controlled trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone in the treatment of Diabetic Foot Ulcers (DFUs) Inclusion Criteria: Wagner 1 Diabetic Foot Ulcer (DFU) extending at least through the dermis provided it is below the medial

  6. Slide 6: Trial Design: Primary Outcome Measure

    Slide 6: Trial Design: Primary Outcome Measure

    Trial Design Primary Outcome Measure * Percentage of wounds closed at 12 weeks defined as complete epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart Closure Determination * Initial closure determined by treating provider and confirmed

  7. Slide 7: Trial Design: Secondary Outcome Measures

    Slide 7: Trial Design: Secondary Outcome Measures

    Trial Design Secondary Outcome Measures: * Percent area reduction (PAR) at 4, 6, 8, and 12 weeks as measured by 3D digital planimetry (eKare, Fairfax, VA) * Quality of life comparison using Wound Quality of Life Score * Pain assessment using Visual Analogue Pain Scale (VAS) * Peripheral neuropathy a

  8. Slide 8: Interim Analysis Trial Results

    Slide 8: Interim Analysis Trial Results

    @ skinte Interim Analysis Trial Results

  9. Slide 9: Analysis: Demographics

    Slide 9: Analysis: Demographics

    Interim Analysis: Demographics ty Enrollment: Demographic Variable __SkinTE soc Patient Age (year) 616 10.25) 59.3 (13.46) es __|* 25 SkinTE patients and 25 SOC patients BMI 32.3756) 33.4754) ose |, <a 13 sites across the US Male 1872) 17,68) 076 Female 7 (28) 8(32) ‘Subject Comorbidities 9.6 (3.29)

  10. Slide 10: Analysis: SkinTE Met Primary Endpoint

    Slide 10: Analysis: SkinTE Met Primary Endpoint

    Interim Analysis: SkinTE Met Primary Endpoint a 8 Percentage of Wounds Closed 6 8 8 -SkinTE -=-SOc SkinTE Group: 18/25 DFUs Closed at 12 Weeks (72%) SOC Group: 8/25 DFUs Closed at 12 a od f Weeks (32%) SA a p=0.005 aes 0 2 4 6 8 10 2 Time (Weeks from Randomization)

  11. Slide 11: Analysis Secondary Endpoint: Percent Area Reduction (PAR)

    Slide 11: Analysis Secondary Endpoint: Percent Area Reduction (PAR)

    Interim Analysis Secondary Endpoint: Percent Area Reduction (PAR) 90 . cS eee 10 a Week SkinTE soc p-value PSHE “PSOE: P8 4 78.6 (35.6) | 24.0 (106.52) | 0.00021 83.2 (40.89) | 43.8(101.98) | 0.004 40 / ¥ \ WA 8 86.6 (39.58) | 47.2 (89.85) 0.002 30 \ = 12 88.2 (39.14) | 49.6 (101.45) 0.012 4 \ VY Pe

  12. Slide 12: Analysis: Secondary Endpoints

    Slide 12: Analysis: Secondary Endpoints

    Interim Analysis: Secondary Endpoints No Significant Difference * Quality of life comparison using Wound Quality of Life Score * Pain assessment using Visual Analogue Pain Scale (VAS) at 12 weeks * Peripheral neuropathy assessment using Semmes- Weinstein Monofilament 10-point discrimination test * C

  13. Slide 13: Analysis: Adverse Events (AEs)

    Slide 13: Analysis: Adverse Events (AEs)

    Interim Analysis: Adverse Events (AEs) * There were 86 AEs allocated to 25 subjects * The SkinTE group had 38 AEs allocated to 11 subjects * SOC group had 48 AEs allocated to 14 subjects ; Inc. All Rights Reserved.

  14. Slide 14: About SkinTE™

    Slide 14: About SkinTE™

    About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient’s own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deploy

Source: SEC EDGAR · 8-K filed Sep 14, 2020

More decks from PolarityTE Inc.